ART27.13, a Peripherally Restricted CB1 Agonist Under Clinical Investigation Targeting Cancer Anorexia & Cachexia Syndrome (CACS)
Time: 12:00 pm
day: Conference Day 1
Details:
- Exploring the scientific and clinical validation of ART27.13, a dual CB1/CB2 agonist, through Phase 1 results and its progression to the Phase 2a CAReS Trial for treating CACS
- Analyzing the formulation of ART27.13, its unique chemical properties, and the intellectual property supporting its peripheral receptor selectivity
- Assessing the unmet need in cancer anorexia and cachexia syndrome (CACS) and the potential impact of ART27.13 in addressing this gap
